Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy

Qin,Caipeng; Liu,Zhenhua; Yuan,Yeqing; Zhang,Xiaowei; Li,Henan; Zhang,Chunfang; Xu,Tao; Wang,Xiaofeng

doi:10.3892/mmr.2014.1896

Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy

Authors:
- Caipeng Qin
- Zhenhua Liu
- Yeqing Yuan
- Xiaowei Zhang
- Henan Li
- Chunfang Zhang
- Tao Xu
- Xiaofeng Wang
View Affiliations

Affiliations: Department of Urology, Peking University People's Hospital, Beijing 100044, P.R. China, Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, P.R. China, Department of Scientific Research, Peking University People's Hospital, Beijing 100044, P.R. China
Published online on: January 14, 2014 https://doi.org/10.3892/mmr.2014.1896
Pages: 851-856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current cancer therapies are largely reliant upon drugs and radiation that kill dividing cells or inhibit cell division in the primary tumor after radical surgery, whereas metastatic tumors should be more commonly the focus of targeted molecular therapies. Glycoprotein non‑metastatic melanoma protein B (Gpnmb) is expressed in various types of cancer, and promotes the migration, invasion and metastasis of tumor cells. Thus, it was hypothesized that a unique clear‑cell renal carcinoma (ccRCC) subclone expressing a high level of Gpnmb may metastasize more easily and thus be associated with poor prognosis. In the present study, the expression of Gpnmb was analyzed in primary and metastatic ccRCC samples, and the expression levels of Gpnmb were significantly higher in metastatic ccRCCs than in matched primary samples (P=0.036). Receiver operating characteristic (ROC) curve analysis was then performed to determine a cutoff score for Gpnmb expression in another 43 primary ccRCCs. For validation, the ROC‑derived cutoff score was subjected to an analysis of the association between Gpnmb expression and patient outcome/clinical characteristics. Kaplan‑Meier analysis demonstrated that elevated Gpnmb expression predicted a poorer overall survival (OS) in 43 cases of primary ccRCC. In addition, multivariate analyses revealed that Gpnmb expression served as an independent risk factor for ccRCC. Thus, the overexpression of Gpnmb identified patients at high risk and Gpnmb is a potential therapeutic molecular target for this type of tumor.

View Figures

View References

1	Tan X, Zhai Y, Chang W, et al: Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer. 123:1080–1088. 2008. View Article : Google Scholar : PubMed/NCBI
2	Fang Y, Wei J, Cao J, et al: Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One. 8:e625582013. View Article : Google Scholar : PubMed/NCBI
3	Minn AJ, Kang Y, Serganova I, et al: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 115:44–55. 2005. View Article : Google Scholar : PubMed/NCBI
4	Nguyen DX and Massagué J: Genetic determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007. View Article : Google Scholar : PubMed/NCBI
5	Laird A, O’Mahony FC, Nanda J, et al: Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One. 8:e604832013. View Article : Google Scholar
6	Abou Youssiff T, Fahmy MA, Koumakpayi IH, et al: The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 117:290–300. 2011.PubMed/NCBI
7	Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol. 33:534–543. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hong SB, Oh H, Valera VA, Baba M, Schmidt LS and Linehan WM: Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One. 5:e157932010. View Article : Google Scholar : PubMed/NCBI
9	Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K and Hearing VJ: Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J. 24:1616–1629. 2010. View Article : Google Scholar : PubMed/NCBI
10	Abdelmagid SM, Barbe MF, Hadjiargyrou M, et al: Temporal and spatial expression of osteoactivin during fracture repair. J Cell Biochem. 111:295–309. 2010. View Article : Google Scholar : PubMed/NCBI
11	Safadi FF, Xu J, Smock SL, Rico MC, Owen TA and Popoff SN: Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem. 84:12–26. 2001. View Article : Google Scholar : PubMed/NCBI
12	Loftus SK, Antonellis A, Matera I, et al: Gpnmb is a melanoblast-expressed, MITF-dependent gene. Pigment Cell Melanoma Res. 22:99–110. 2009. View Article : Google Scholar : PubMed/NCBI
13	Tan X, He S, Han Y, et al: Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients. Cancer Cell Int. 13:202013. View Article : Google Scholar : PubMed/NCBI
14	Ohno Y, Izumi M, Tachibana M, et al: Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines. Oncol Rep. 20:501–509. 2008.PubMed/NCBI
15	Karashima T, Fukuhara H, Tamura K, et al: Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. Int J Urol. 20:923–930. 2013. View Article : Google Scholar
16	Saw RP, Morgan M, Koorey D, et al: p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 46:192–202. 2003. View Article : Google Scholar
17	Jones J, Otu H, Spentzos D, et al: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
18	Kosari F, Parker AS, Kube DM, et al: Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 11:5128–5139. 2005. View Article : Google Scholar : PubMed/NCBI
19	Wang J, Chen A, Yang C, Zeng H, Qi J and Guo FJ: A bone-seeking clone exhibits different biological properties from the ACHN parental human renal cell carcinoma in vivo and in vitro. Oncol Rep. 27:1104–1110. 2012.PubMed/NCBI
20	Thompson RH, Gillett MD, Cheville JC, et al: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 104:2084–2091. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zigeuner R, Ratschek M, Rehak P, Schips L and Langner C: Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 63:651–655. 2004. View Article : Google Scholar : PubMed/NCBI
22	Schultz L, Chaux A, Albadine R, et al: Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol. 35:1549–1556. 2011. View Article : Google Scholar
23	Abel EJ, Culp SH, Tannir NM, et al: Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 59:10–15. 2011. View Article : Google Scholar
24	Tse KF, Jeffers M, Pollack VA, et al: CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res. 12:1373–1382. 2006. View Article : Google Scholar : PubMed/NCBI
25	Rich JN, Shi Q, Hjelmeland M, et al: Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem. 278:15951–15957. 2003. View Article : Google Scholar
26	Kuan CT, Wakiya K, Dowell JM, et al: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 12:1970–1982. 2006. View Article : Google Scholar
27	Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M and Siegel PM: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res. 5:1001–1014. 2007. View Article : Google Scholar : PubMed/NCBI
28	Onaga M, Ido A, Hasuike S, et al: Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol. 39:779–785. 2003. View Article : Google Scholar : PubMed/NCBI
29	Ripoll VM, Irvine KM, Ravasi T, Sweet MJ and Hume DA: Gpnmb is induced in macrophages by IFN-γ and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol. 178:6557–6566. 2007.PubMed/NCBI
30	Tomihari M, Hwang SH, Chung JS, Cruz PD Jr and Ariizumi K: Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol. 18:586–595. 2009. View Article : Google Scholar : PubMed/NCBI